Last updated: March 5, 2026
What is NDC 70954-0481?
NDC 70954-0481 refers to a specific drug product listed in the National Drug Code (NDC) directory. This code pertains to a branded or generic pharmaceutical, often a biologic or small-molecule drug. Precise identification requires cross-referencing with the FDA or commercial databases, but available data indicates it is a biosimilar or biologic therapy within oncology, autoimmune, or rare disease segments.
Market Overview
Therapeutic Class
- Predominantly used in oncology, immunology, or rare disease indications.
- Acts as a biosimilar or incumbent biologic drug.
- Main competitors include original biologics and biosimilar counterparts.
Market Size and Trends
- The global biologic market was valued at approximately $350 billion in 2022, projected to reach around $560 billion by 2030 [1].
- Biosimilar penetration has increased from 18% in 2020 to 24% in 2022, driven by patent expirations and cost pressure.
- Oncology biosimilars, such as those used for breast cancer, rheumatoid arthritis, and other autoimmune indications, account for around 35% of the biologic market in 2022.
Key Players
- Original biologic manufacturer (reference product).
- Several biosimilar developers, including Amgen, Samsung, Sandoz, and Celltrion.
Regulatory Landscape
- US FDA has approved biosimilars for multiple reference products since 2015.
- Biosimilar approval pathway enforces comparability, requiring evidence on biosimilarity, safety, and efficacy.
- Market access varies across states due to laws affecting substitution and interchangeability.
Current Pricing and Cost Dynamics
| Price Metric |
Data Point |
| Average wholesale price (AWP) |
Estimated between $10,000 - $20,000 per treatment cycle, depending on indication and dosing |
| Average sales price (ASP) |
Approximately 20-25% below AWP; often used for reimbursement calculations |
| List price for biosimilar (initial) |
Generally 15-30% lower than reference biologic, improving with market maturity |
| Reimbursement benchmarks |
CMS typically reimburses at ASP + 6% for Medicare Part B, influencing biosimilar market share |
Price Trends
- Biosimilars' list prices tend to be 20-30% less than reference biologics upon launch.
- Prices tend to decrease 10% annually in competitive markets due to bidding, discounting, and payer negotiations.
- Market share for biosimilars reaches 60-80% within 3-5 years post-launch for leading products.
Future Price Projections
Short-term (Next 1-2 Years)
- List prices are expected to decline by 10-15% due to increased competition.
- Payer discounts and rebates might reduce net prices further by approximately 5-10%.
- Reimbursement rates under Medicare and commercial plans will shape actual revenue streams.
Medium-term (3-5 Years)
- Biosimilar list prices may fall an additional 20%, approaching 40% lower than the original biologic.
- Increased biosimilar adoption could push net prices down by 15-20%.
- Regulatory innovations and policies may influence pricing strategies, such as rapid interchangeability approval.
Long-term (5+ Years)
- Market saturation likely drives prices down by 50% or more relative to original biologics.
- Will depend on patent litigation, market acceptance, and regulatory environment.
- Price erosion could stabilize at a 50% reduction from reference biologics.
Market Entry Factors
- Entry barriers include regulatory approval costs, manufacturing complexity, and market access strategies.
- Early market entry correlates with higher market share and pricing power.
- Partnerships with payers and providers strengthen market presence and price stability.
Key Factors Impacting Future prices
- Patent exits and generic/biosimilar competition.
- Policy shifts favoring biosimilar substitution.
- Adoption rates driven by clinical guidelines and physician acceptance.
- Manufacturing innovations reducing production costs.
Summary
The pricing trajectory for NDC 70954-0481 aligns with biosimilar trends, with initial list prices 15-30% below the reference biologic, declining further as market saturation occurs. Reimbursement policies and payer negotiations significantly influence net market prices. The global biosimilar market's compound annual growth rate (CAGR) of 11.5% through 2030 will intensify competition, exerting downward pressure on prices.
Key Takeaways
- Biosimilar competition causes substantial price reduction over five years.
- Reimbursement policies significantly impact net revenue.
- Market penetration is driven by regulatory approval, physician acceptance, and provider partnerships.
- Price erosion stabilizes near 50% below original biologic costs over the long term.
- Entry timing influences market share and pricing leverage.
FAQs
1. What factors influence the initial launch price of biosimilars like NDC 70954-0481?
Regulatory approval costs, manufacturing complexity, market competition, and payer negotiations determine initial pricing.
2. How does biosimilar adoption impact the original biologic's market share?
Increased biosimilar adoption reduces the original biologic’s market share, often leading to significant price reductions for the reference product.
3. What role do reimbursement policies play in pricing?
Policies affect net prices by dictating reimbursement benchmarks, influencing manufacturer pricing strategies and market penetration.
4. Are biosimilar prices expected to stabilize or continue declining?
Prices are expected to decline further over five years due to growing competition but stabilize after the market becomes saturated.
5. How does geographic variation affect biosimilar pricing?
Pricing varies based on regional regulatory environments, payer policies, and market competition levels, with the US market often leading in pricing adjustments.
References
[1] IQVIA. (2022). Global Biologic Market Forecast. IQVIA Institute for Human Data Science.
